By Hans Baer
There are literally trillions of microorganisms that live in the human digestive system and are believed to affect our health. These microorganisms include countless types of bacteria, viruses and fungi. While most of the hundreds of bacteria that reside in the gut and have been studied are beneficial, some are pathogenic.
The development of microbiota-targeted therapies and other microbiome-based products creates significant opportunities to improve human health and well-being. Firstly, there are several diseases that are thought to be influenced by microbial processes that occur within the gut. This includes many types of cancer, as well as autoimmune disorders such as multiple sclerosis. The gut microbiome can also influence the effects of various drug products such as mental health therapeutics. Finally, improved microbiome targeting solutions may be the key to enhance patient care for a range of therapeutic areas.
As a global leader for oral drug delivery, Evonik has developed a broad, versatile portfolio of functional excipients, drug delivery technologies and services for formulation development and cGMP manufacturing that can create value for microbiota-targeted therapies and other microbiome-based products.